Brazil Scleroderma Therapeutics Market Size & Outlook
Related Markets
Brazil scleroderma therapeutics market highlights
- The Brazil scleroderma therapeutics market generated a revenue of USD 57.6 million in 2024 and is expected to reach USD 84.7 million by 2030.
- The Brazil market is expected to grow at a CAGR of 6.3% from 2025 to 2030.
- In terms of segment, immunosuppressors was the largest revenue generating drug class in 2024.
- Endothelin Receptor Antagonists is the most lucrative drug class segment registering the fastest growth during the forecast period.
Scleroderma therapeutics market data book summary
| Market revenue in 2024 | USD 57.6 million |
| Market revenue in 2030 | USD 84.7 million |
| Growth rate | 6.3% (CAGR from 2025 to 2030) |
| Largest segment | Immunosuppressors |
| Fastest growing segment | Endothelin Receptor Antagonists |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunosuppressors, Phosphodiesterase 5 inhibitors - PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics |
Other key industry trends
- In terms of revenue, Brazil accounted for 2.3% of the global scleroderma therapeutics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil scleroderma therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 84.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Scleroderma Therapeutics Market Scope
Scleroderma Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Emerald Health Pharmaceuticals | View profile | 11-50 | San Diego, California, United States, North America | https://emeraldpharma.life |
| Chemomab | View profile | 11-50 | Tel Aviv, Tel Aviv, Israel, Asia | http://chemomab.com |
| Calliditas Therapeutics | View profile | 51-100 | Stockholm, Stockholms Lan, Sweden, Europe | https://www.calliditas.se/ |
| Corbus Pharmaceuticals | View profile | 51-100 | Norwood, Massachusetts, United States, North America | http://corbuspharma.com |
| Bristol-Myers Squibb Company | View profile | - | - | - |
| Cytori Therapeutics | View profile | 51-100 | San Diego, California, United States, North America | https://www.cytori.com/ |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Roche Holding AG ADR | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
Brazil scleroderma therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to scleroderma therapeutics market will help companies and investors design strategic landscapes.
Immunosuppressors was the largest segment with a revenue share of 29.51% in 2024. Horizon Databook has segmented the Brazil scleroderma therapeutics market based on immunosuppressors, phosphodiesterase 5 inhibitors - pha, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers, analgesics covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Brazil scleroderma therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Brazil scleroderma therapeutics market databook
-
Our clientele includes a mix of scleroderma therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil scleroderma therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Brazil scleroderma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Brazil scleroderma therapeutics market size, by systemic scleroderma, 2018-2030 (US$M)
Brazil Scleroderma Therapeutics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
